Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VANI Stock Forecast 2025-2026
$1.05
Current Price
$62.21M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VANI Price Targets
+281.0%
To High Target of $4.00
+281.0%
To Median Target of $4.00
+281.0%
To Low Target of $4.00
VANI Price Momentum
+2.9%
1 Week Change
-5.4%
1 Month Change
-35.6%
1 Year Change
-9.5%
Year-to-Date Change
-49.8%
From 52W High of $2.09
+16.0%
From 52W Low of $0.90
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Vivani (VANI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VANI and similar high-potential opportunities.
Latest VANI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, VANI has a bullish consensus with a median price target of $4.00 (ranging from $4.00 to $4.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.05, the median forecast implies a 281.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 281.0% upside. Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 281.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VANI Analyst Ratings
2
Buy
0
Hold
0
Sell
VANI Price Target Range
Low
$4.00
Average
$4.00
High
$4.00
Current: $1.05
Latest VANI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VANI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $4.00 |
| Apr 4, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $4.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $4.00 |
| Mar 13, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $4.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $3.00 |
| Dec 5, 2022 | ThinkEquity | Ashok Kumar | Buy | Initiates | $7.00 |
Vivani Medical Inc. (VANI) Competitors
The following stocks are similar to Vivani based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vivani Medical Inc. (VANI) Financial Data
Vivani Medical Inc. has a market capitalization of $62.21M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -122.4%.
Valuation Metrics
Market Cap
$62.21M
Enterprise Value
$63.17M
P/E Ratio
0.0x
PEG Ratio
-1.9x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+29.5%
Current Ratio
3.4x
Debt/Equity
109.7x
ROE
-122.4%
ROA
-35.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Vivani Medical Inc. (VANI) Business Model
About Vivani Medical Inc.
What They Do
Develops innovative healthcare solutions with bioelectronics.
Business Model
Vivani Medical Inc. generates revenue by creating and commercializing implantable medical devices aimed at treating chronic diseases and improving patient outcomes. The company focuses on bioengineering technologies to address sensory deficits and chronic pain, thus capitalizing on the growing demand for advanced medical solutions.
Additional Information
Vivani Medical operates in a promising sector that combines bioengineering and healthcare, with applications in neuroscience and chronic disease management. Their commitment to innovation positions them well in the evolving landscape of medical technology and bioelectronic medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
37
CEO
Dr. Adam Mendelsohn Ph.D.
Country
United States
IPO Year
2022
Website
www.vivani.comVivani Medical Inc. (VANI) Latest News & Analysis
Latest News
Quick Summary
Over 50% of dogs in the U.S. are overweight or obese, leading to higher risks of chronic diseases and shorter lifespans. This trend may impact pet care and health-related markets.
Why It Matters
Rising pet obesity trends suggest increased demand for health-focused pet products and services, impacting related industries and investment opportunities in pet care and wellness sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
28 days ago
Quick Summary
The LIBERATE-1 study of NPM-115 (exenatide implant) has completed full enrollment and initial administration in obese and overweight subjects, with top-line data anticipated by mid-2025.
Why It Matters
Successful enrollment in the LIBERATE-1 study indicates potential for breakthrough obesity treatment. Positive data could boost stock value and market confidence in the company's pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Vivani Medical, Inc. plans to raise approximately $8.25 million through a private placement of 7.37 million shares at $1.12 each, strengthening its balance sheet and funding NPM-139 development.
Why It Matters
The financing enhances Vivani's balance sheet and extends its operational runway, supporting the development of its GLP-1 implant, which could drive future revenue growth and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NanoPortal™ technology has successfully delivered semaglutide in a preclinical study, which may impact the development of treatments like Ozempic® and Wegovy®.
Why It Matters
Successful delivery of semaglutide via NanoPortal™ could enhance drug efficacy and market potential, impacting pharmaceutical valuations and investor sentiment in obesity and diabetes treatment sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Vivani Medical, Inc. (NASDAQ: VANI) will present at the Emerging Growth Conference on March 27, 2025, inviting investors and analysts to join its interactive online event.
Why It Matters
Vivani Medical's presentation at the Emerging Growth Conference highlights its potential for innovation in drug delivery, attracting interest from investors and analysts, which could impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
What Makes Vivani Medical (VANI) a New Buy Stock
1 month ago
Quick Summary
Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects.
Why It Matters
Vivani Medical's upgrade to a Zacks Rank #2 signals positive earnings potential, likely attracting more investor interest and potentially driving stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About VANI Stock
What is Vivani Medical Inc.'s (VANI) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Vivani Medical Inc. (VANI) has a median price target of $4.00. The highest price target is $4.00 and the lowest is $4.00.
Is VANI stock a good investment in 2025?
According to current analyst ratings, VANI has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VANI stock?
Wall Street analysts predict VANI stock could reach $4.00 in the next 12 months. This represents a 281.0% increase from the current price of $1.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vivani Medical Inc.'s business model?
Vivani Medical Inc. generates revenue by creating and commercializing implantable medical devices aimed at treating chronic diseases and improving patient outcomes. The company focuses on bioengineering technologies to address sensory deficits and chronic pain, thus capitalizing on the growing demand for advanced medical solutions.
What is the highest forecasted price for VANI Vivani Medical Inc.?
The highest price target for VANI is $4.00 from Yi Chen at HC Wainwright & Co., which represents a 281.0% increase from the current price of $1.05.
What is the lowest forecasted price for VANI Vivani Medical Inc.?
The lowest price target for VANI is $4.00 from Yi Chen at HC Wainwright & Co., which represents a 281.0% increase from the current price of $1.05.
What is the overall VANI consensus from analysts for Vivani Medical Inc.?
The overall analyst consensus for VANI is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are VANI stock price projections?
Stock price projections, including those for Vivani Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 7:56 AM UTC